Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
July 10 2017 - 4:01PM
Business Wire
Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of
innovative treatments for aortic disorders, today announced that
John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief
Financial Officer, will present at the Canaccord Genuity 37th
Annual Growth Conference at 2:30 p.m. ET on Wednesday, August 9,
2017 in Boston, MA.
A live webcast of the presentation will be accessible through
the “Investors” section of the Company’s website at
www.endologix.com and will be available for replay following the
event.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
80%, making it a leading cause of death in the United States. For
more information, visit www.endologix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170710005977/en/
INVESTORS:Endologix, Inc.Vaseem Mahboob, CFO,
949-595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024